Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments

Area of Science:

• Hepatology
• Gastroenterology
• Epidemiology

Background:

• Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum from simple fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) and cirrhosis.
• NAFLD is the primary driver of chronic liver disease in Western populations, with rising incidence linked to increasing rates of type 2 diabetes and obesity.

Purpose of the Study:

• This review synthesizes current scientific knowledge on the epidemiology, diagnosis, and management of NAFLD.
• To provide an overview of the latest findings and therapeutic strategies for NAFLD.

Main Methods:

• Review of epidemiological data on NAFLD prevalence and risk factors.
• Analysis of current diagnostic approaches for NAFLD.
• Evaluation of established and emerging therapeutic interventions for NAFLD.

Main Results:

• Lifestyle modifications, including weight reduction through Mediterranean diets and exercise, are central to NAFLD management.
• Pharmacological treatments show potential for patients with NASH and fibrosis, particularly non-responders to lifestyle interventions.
• Currently, no specific pharmacological agents are FDA-approved for treating NASH.

Conclusions:

• NAFLD is a significant public health issue requiring comprehensive management strategies.
• Lifestyle interventions remain the cornerstone of NAFLD treatment.
• Further research and development are needed for approved pharmacological therapies for NASH.